Tesamorelin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tesamorelin
Tesamorelin.svg
Clinical data
Trade namesEgrifta
AHFS/Drugs.comMultum Consumer Information
MedlinePlusa611035
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability≤4%[1]
MetabolismProteolysis
Elimination half-life26–38 min
ExcretionRenal/proteolysis
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC221H366N72O67S
Molar mass5135.86 g/mol g·mol−1
3D model (JSmol)

Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.[2]

See also[edit]

References[edit]

  1. ^ "Egrifta (tesamorelin for injection) for Subcutaneous Use. U.S. Full Prescribing Information" (PDF). EMD Serono, Inc. Retrieved 9 April 2016.
  2. ^ "FDA Application Chemistry Review" (PDF).